Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Anup Zutshi"'
Publikováno v:
Heliyon, Vol 7, Iss 7, Pp e07649- (2021)
Affinity (KD) optimization of monoclonal antibodies is one of the factors that impacts the stoichiometric binding and the corresponding efficacy of a drug. This impacts the dose and the dosing regimen, making the optimum KD a critical component of dr
Externí odkaz:
https://doaj.org/article/8f707839c01d44afb34fec99d6fc0310
Publikováno v:
IFAC-PapersOnLine. 55:175-179
Here we present details of the calculation necessary to estimate the impact of avidity in a mathematical model of a bispecific antibody with two membrane-bound targets. The calculation is used to reproduce the results reported in Rhoden et al. (2016)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbab2d42dd2586e77f79ea020c52391f
https://doi.org/10.1101/2022.09.12.507653
https://doi.org/10.1101/2022.09.12.507653
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Immunosuppressive drugs can alleviate debilitating symptoms of autoimmune diseases, but, by the same token, excessive immune suppression can result in an increased risk of infection. Despite the dangers of a compromised immune system, clear definitio
Autor:
Wanping Geng, Christian Wichmann, Yit Wooi Goh, Angela Rigopoulos, Diana Cao, Linghui Li, Hui K Gan, Yan Lan, Nhi Huynh, Fiona Scott, Andrew M. Scott, Alexander Franklin McDonald, Anup Zutshi, Zhanqi Liu, Sylvia J. Gong, Nancy Guo, Uwe Ackermann, Ingrid Burvenich, Graeme O'Keefe
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:3075-3088
Τhis study aimed to optimize the 89Zr-radiolabelling of bintrafusp alfa investigational drug product and controls, and perform the in vitro and in vivo characterization of 89Zr-Df-bintrafusp alfa and 89Zr-Df-control radioconjugates. Bintrafusp alfa
Publikováno v:
Heliyon, Vol 7, Iss 7, Pp e07649-(2021)
Heliyon
Heliyon
Affinity (KD) optimization of monoclonal antibodies is one of the factors that impacts the stoichiometric binding and the corresponding efficacy of a drug. This impacts the dose and the dosing regimen, making the optimum KD a critical component of dr
Autor:
Anup Zutshi, Berend Neuteboom, Seema Kumar, Willem Sloot, Christine Knuehl, Julia Dotterweich, Jianguo Ma, Christiane Amendt, Karthik Venkatakrishnan, Taeshin Park, John Pappas, Kyoung-Ae Kim
Publikováno v:
Cancer Research. 82:5423-5423
Introduction: M1231 is a first-in-class bispecific antibody drug conjugate (ADC) targeting mucin-1 (MUC1) and epidermal growth factor receptor (EGFR), that is conjugated with a novel hemiasterlin-related microtubule inhibitor payload. Following dose,
Publikováno v:
Progress in Biophysics and Molecular Biology. 139:59-72
System based pharmacokinetic (PK) models can be used to study and predict the distribution of antibody based drugs into target tissues and assess the pharmacobinding (PB) of the drug to the target and the subsequent pharmacodynamic (PD) changes. In t
Autor:
Ingrid Julienne Georgette, Burvenich, Yit Wooi, Goh, Nancy, Guo, Hui Kong, Gan, Angela, Rigopoulos, Diana, Cao, Zhanqi, Liu, Uwe, Ackermann, Christian Werner, Wichmann, Alexander Franklin, McDonald, Nhi, Huynh, Graeme Joseph, O'Keefe, Sylvia Jie, Gong, Fiona Elizabeth, Scott, Linghui, Li, Wanping, Geng, Anup, Zutshi, Yan, Lan, Andrew Mark, Scott
Publikováno v:
European journal of nuclear medicine and molecular imaging. 48(10)
Τhis study aimed to optimize theBintrafusp alfa (anti-PD-L1 human IgG1 antibody fused to TGF-β receptor II (TGF-βRII), avelumab (anti-PD-L1 human IgG1 control antibody), isotype control (mutated inactive anti-PD-L1 IgG1 control antibody), and trap
Autor:
Helene Lelievre, Avijit Ray, Dean Bottino, Anup Zutshi, John P. Gibbs, Chirag Patel, Alex Rolfe, Marjoleen Nijsen, Brian Stoll, Alix Scholer-Dahirel, Christoph Niederalt, Sylvain Fouliard, Tomoki Yoneyama, Hoa Q Nguyen, Andy Z. X. Zhu, Sumit Bhatnagar, Christian Scheerans, Senthil Kabilan, Rolf Burghaus, Filippo Venezia, Jörg Lippert, Natalya Belousova, Serguei Soukharev, R. Adam Thompson, Jared Weddell, Georgia Lazarou, Vijayalakshmi Chelliah, Akihiro Yamada, Sabrina Collins, Haiqing Wang, Abhishek Gulati, Andrzej M. Kierzek, Heike Oberwittler, Marylore Chenel, Masayo Oishi, Piet H. van der Graaf, Sabine Wittemer-Rump, Irina Kareva, Hiroyuki Sayama
Publikováno v:
Clinical Pharmacology and Therapeutics
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno-oncology (IO) the aim is to direct the patient's own immune system to fight cancer. After